Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, Hunan, China.
Clin Pharmacol Ther. 2020 Aug;108(2):242-247. doi: 10.1002/cpt.1844. Epub 2020 Apr 21.
An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.
2019 年新型冠状病毒（2019-nCoV）感染疫情在全球范围内蔓延。目前尚无针对 COVID-19 的特效抗病毒药物。除了推荐的抗病毒药物（如干扰素-α、洛匹那韦/利托那韦、利巴韦林和磷酸氯喹）外，还登记和启动了一些针对病毒 RNA 依赖性 RNA 聚合酶（RdRp）抑制剂的临床试验。法匹拉韦是一种嘌呤核苷酸类似物和有效的 RdRp 抑制剂，已获准用于流感，在几项临床试验中也被认为是有效的。在此，我们从药物代谢的角度总结了法匹拉韦的药代动力学特征和可能的药物相互作用。我们希望这有助于设计 COVID-19 中法匹拉韦的临床试验，因为体外病毒抑制和临床前动物研究的疗效数据仍不可用。
Zotero 插件